INMB director options reset to $1.50 under 2017–2021 incentive plans
Rhea-AI Filing Summary
Inmune Bio, Inc. (INMB) reported a stock option repricing for a director effective as of November 18, 2025. Stockholders approved a one-time adjustment that reduced the exercise price of certain outstanding stock options granted under the company’s 2017, 2019 and 2021 stock incentive plans to $1.50 per share, matching the closing price of Inmune Bio’s common stock on The Nasdaq Capital Market on that date. The filing shows multiple stock option awards where higher exercise prices were replaced by new options at $1.50, while all other terms, including vesting schedules and expiration dates, remain unchanged and continue to depend on the director’s ongoing service.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (right to buy) | 108,000 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 108,000 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 108,000 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 108,000 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 15,975 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 15,975 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 19,025 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 19,025 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 35,000 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 35,000 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 35,000 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 35,000 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 32,500 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 32,500 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 12,500 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 12,500 | $0.00 | -- |
Footnotes (1)
- Effective as of November 18, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2017 Stock Incentive Plan (the "2017 Plan"), 2019 Stock Incentive Plan (the "2019 Plan"), and Second Amended and Restated 2021 Stock Incentive Plan (as may be amended, restated or otherwise modified from time to time in accordance with its terms, the "2021 Plan") , which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
FAQ
What did Inmune Bio (INMB) report in this Form 4 filing?
Inmune Bio reported that a director’s existing stock options were repriced as of November 18, 2025, with multiple awards having their exercise prices reduced to $1.50 per share under previously approved stock incentive plans.
What is the new exercise price of the repriced stock options for INMB?
The repriced stock options now carry an exercise price of $1.50 per share, which represents the closing price of Inmune Bio’s common stock on The Nasdaq Capital Market on November 18, 2025.
Which stock incentive plans were affected by Inmune Bio's option repricing?
The repricing applies to certain outstanding stock options granted under Inmune Bio’s 2017 Stock Incentive Plan, 2019 Stock Incentive Plan, and Second Amended and Restated 2021 Stock Incentive Plan.
Did the vesting terms change for the repriced INMB stock options?
No. The filing states that, apart from the reduced exercise price, all other terms and conditions of the repriced options, including vesting and term, remain in full force and effect and depend on the director’s continued service.
Who is the reporting person in this Inmune Bio Form 4 filing?
The reporting person is identified as a director of Inmune Bio, Inc. and filed the Form 4 as a single reporting person. The signature block shows /s/ Timothy Schroeder as the signatory.
Does this INMB filing involve new option grants or only repricing existing options?
The filing describes a one-time repricing of certain outstanding stock options, reducing their exercise price to $1.50 while keeping existing terms in place, rather than creating entirely new awards with different conditions.